Valuation: PMV Pharmaceuticals, Inc.

Market Cap 135M 120M 112M 102M 193M 12.99B 194M 1.36B 526M 6.64B 507M 496M 21.32B P/E 2026 *
-1.46x
P/E 2027 * -1.95x
Enterprise Value 135M 120M 112M 102M 193M 12.99B 194M 1.36B 526M 6.64B 507M 496M 21.32B EV / Sales 2026 *
-
EV / Sales 2027 * 26.9x
Free-Float
97.64%
Yield 2026 *
-
Yield 2027 * -
1 day+2.29%
1 week+34.59%
Current month+7.19%
1 month+44.35%
3 months+46.72%
6 months+33.58%
Current year+43.20%
1 week 1.3
Extreme 1.3
1.91
1 month 1.28
Extreme 1.28
1.91
Current year 1.02
Extreme 1.02
1.91
1 year 1.02
Extreme 1.02
1.91
3 years 0.81
Extreme 0.81
6.66
5 years 0.81
Extreme 0.81
30.4
10 years 0.81
Extreme 0.81
63.22
Manager TitleAgeSince
Chief Executive Officer 64 2013-06-30
Director of Finance/CFO 52 2024-01-04
Chief Tech/Sci/R&D Officer - 2020-11-30
Director TitleAgeSince
Director/Board Member 86 2013-05-31
Director/Board Member 64 2013-05-31
Chairman 58 2026-06-03
Date Insider Type Main position Quantity % Market Cap. Importance
3/5/26 Other

Chief Financial Officer

240,000 0.4510%
3/5/26 Free

Chief Operating Officer

319,270 0.6000%
3/5/26 Free

Founder

744,960 1.4000%
Change 5-day change 1-year change 3-year change Capi.($)
+2.29%+34.59%+24.31%-70.12% 135M
+4.16%+3.04%+49.37%+94.17% 74.16B
-3.11%-3.53%+20.19%+81.44% 57.39B
+0.89%-0.63%+2.17%+36.19% 47.64B
+0.36%+0.81%+342.39%+742.40% 44.29B
-0.96%-4.50%+24.96%+35.38% 42.5B
-0.20%-0.77%+4.13%+105.50% 40.71B
-0.54%+2.93%+9.31%+50.41% 30.97B
-2.68%+2.92%+29.33%+22.72% 28.53B
+0.05%-1.64%-8.14%-11.37% 24.34B
Average +0.03%+2.93%+49.80%+108.67% 39.07B
Weighted average by Cap. +0.12%-0.83%+56.95%+138.19%

Financials

2026 *2027 *
Net sales - 5.03M 4.47M 4.17M 3.8M 7.17M 484M 7.24M 50.5M 19.57M 247M 18.89M 18.48M 794M
Net income -75.59M -67.16M -62.68M -57.13M -108M -7.27B -109M -759M -294M -3.71B -284M -278M -11.92B -78.37M -69.63M -64.99M -59.23M -112M -7.53B -113M -786M -305M -3.85B -294M -288M -12.36B
Net Debt - -
Logo PMV Pharmaceuticals, Inc.
PMV Pharmaceuticals, Inc. is a precision oncology company engaged in the discovery and development of small molecule, tumor-agnostic therapies targeting p53. p53 is a well-defined tumor suppressor protein known as the guardian of the genome, and normal, or wild-type, p53 has the ability to eliminate cancer cells. However, mutant p53 proteins can be misfolded and lose their wild-type tumor suppressing function. These p53 mutations are found in approximately half of all cancers. The Company is deploying its precision oncology platform to target p53 mutations and other p53-related cancers. Its lead product candidate, rezatapopt, is an orally available small molecule designed to potently and selectively correct p53 misfolding caused by a specific p53 mutation, Y220C, while sparing wild-type p53. In addition to its rezatapopt program, the Company is focused on developing a pipeline of product candidates targeting other p53 mutations or p53-related targets.
Employees
54
Date Price Change Volume
26-10-02 US$1.790 +2.29% 3,735,853
26-10-01 US$1.750 +4.79% 1,647,431
26-09-30 US$1.670 +16.78% 3,125,248
26-09-29 US$1.430 +5.15% 550,859
26-09-28 US$1.360 +2.26% 341,564
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.790USD
Average target price
4.200USD
Spread / Average Target
+134.64%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PMVP Stock